Pluristem Therapeutics IND Cleared by FDA for PLX Cells in COVID-19 Treatment
From Pluristem Therapeutics (PSTI) we learned that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 2 study of its PLX cells in the treatment of severe COVID-19 cases complicated by Acute Respiratory . . .
This content is for paid subscribers.
Impacting News May 8, 2020